More than two thirds of global cancer deaths occur in LMICs due in part to delayed diagnosis and lack of access to specialized staff, chemotherapy and radiation.(Livingston, 2013) Cutaneous malignancies are common and morbid in LMICs, particularly for people living with HIV.(Bray et al., 2018, McMahon et al., 2020) People living with HIV develop more AIDS-defining and non-AIDS defining skin cancers compared to the general population, including Kaposi sarcoma (KS), human papillomavirus (HPV)-associated squamous cell carcinomas, cutaneous lymphoma, keratinocyte carcinomas and melanoma.(Chelidze et al., 2019, Jaquet et al., 2015, WHO, 2014) KS in particular continues to be the leading cause of cancer incidence and mortality across the general population of Malawi, Mozambique, Uganda, and Zambia.(Bray et al., 2018) Although the majority of people living with HIV reside in LMICs – including 25.6 million people in sub-Saharan Africa – little is known about LMIC capacity to diagnose and manage skin cancers.